Ruxolitinib for myelofibrosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Navigating 'grey areas' and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT.Bone marrow transplantation · 2025
   Review
2. Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension.Clinical lymphoma, myeloma & leukemia · 2015
   Article
3. Practical management of patients with myelofibrosis receiving ruxolitinib.Expert review of hematology · 2013
   Review
4. Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome.Clinics (Sao Paulo, Brazil) · 2013
   Article

Corrections and comments

• Comment on
  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.2012

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as